Filing Flows › 8-K events › Avalo Therapeutics
Avalo Therapeutics: entry into a material definitive agreement
Form 8-K filed Nov 5, 2026 · items 1.01, 1.02
What the filing says
On November 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Jefferies Sales Agreement”), with Jefferies LLC (“Jefferies”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discreti
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 1.02: 0.0% next session across 2,368. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.
Avalo Therapeutics at a glance
Avalo Therapeutics, Q4 2025: revenue $59K (-69% year over year). The chart follows the revenue to costs, profit and cash.
Avalo Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.